← Human Trials & Peer-Reviewed Studies
Comparison of methylene blue dye-based chromoendoscopy and Fujifilm virtual chromoendoscopy (blue light imaging and linked color imaging) for dysplasia detection in inflammatory bowel disease: a prospective single-center randomized study
Plain-language guide to PMID 41981491 (2026): randomized controlled trial study of Methylene blue (non-peptide stack partner) in 30 patients.
Key Facts
- PMID
- 41981491
- Journal
- BMC gastroenterology
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Alshatti Y et al. (20 authors)
- DOI
- 10.1186/s12876-026-04828-z
What This Study Did, in Plain Language
What Was Tested
Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.
This study aimed to compare dysplasia detection using methylene blue dye-based chromoendoscopy (MB-CE) and Fujifilm virtual chromoendoscopy (blue light imaging [BLI] and linked color imaging [LCI]) during IBD surveillance colonoscopy.
Why It Was Studied
Prospective data directly comparing these techniques on a single imaging platform remain limited.
METHODS: This was a prospective, randomized, single-center study conducted at Al Adan Hospital, Kuwait.
Who Took Part
The abstract describes 30 patients taking part.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Three hundred adult patients with ulcerative colitis or Crohn’s colitis scheduled for surveillance colonoscopy were randomized 1:1 to MB-CE or BLI/LCI (150 per group).
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.
What Was Measured
Topics PubMed links to this paper include Methylene Blue, Colonoscopy, Blue Light, Coloring Agents, Inflammatory Bowel Diseases, Colitis, Ulcerative and Crohn Disease.
Author keywords: Blue light imaging, Chromoendoscopy, Colorectal cancer, Dysplasia surveillance, Fujifilm ELUXEO and Linked color imaging.
What This Means in Plain Language
The paper is a randomized study of Methylene blue (non-peptide stack partner) in 30 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2026 (BMC gastroenterology), a journal based in England.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.